文献速递性腺与生殖内分泌

澳大利亚中年女性研究:绝经过渡期症状的患病率与严重程度

Prevalence and severity of symptoms across the menopause transition: cross-sectional findings from the Australian Women's Midlife Years (AMY) Study.
PubMed 文献 · Lancet Diabetes Endocrinol · 2025-07-25

澳大利亚AMY研究为全国代表性横断面研究,纳入8096名40-69岁女性,用MENQOL问卷评估绝经相关症状。

要点

  • 中度至重度潮热可可靠提示围绝经期开始,尤其对月经稀发或闭经女性。
  • 阴道干涩是绝经过渡中最具区分度的性相关症状。
  • 其他症状如记忆差、情绪低落受多因素影响,管理需综合考虑。

核心结论

  • 中度至重度令人烦恼的血管舒缩症状可可靠指示围绝经期开始,尤其对月经稀发或闭经女性。
  • 其他症状可能由绝经引起或加重,但需考虑其他因素并纳入管理与照护。

研究设计与样本

  • 澳大利亚AMY研究为全国代表性横断面研究,2023年10月27日至2024年3月19日通过在线和离线非概率小组招募40-69岁女性。
  • 共纳入8096名女性,其中5509名按STRAW+10分类为绝经前(n=1250)、围绝经早期(n=344)、围绝经晚期(n=271)和绝经后(n=3644)。
  • 使用MENQOL问卷评估过去4周症状患病率和严重程度,计算95%CI及调整年龄、BMI等变量的患病率比。

关键数值与推荐

  • STRAW+10标准根据月经周期频率变化定义绝经前至围绝经晚期。
  • MENQOL问卷评估过去4周症状患病率和严重程度。

临床怎么用

  • 对月经稀发或闭经女性,中度至重度潮热可作为围绝经期开始的可靠指标。
  • 管理其他症状时需考虑绝经外因素,并重视治疗选择和照护路径以改善围绝经期健康。

局限性

  • 横断面设计无法确定因果关系。
  • 非概率小组招募可能影响代表性。
  • 仅纳入能完成英文问卷者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The premenopause-to-perimenopause transition is defined by the Stages of Reproductive Aging Workshop +10 (STRAW+10) criteria according to changed menstrual cycle frequency. However, this approach is unhelpful for women and gender-diverse people with oligomenorrhoea or amenorrhoea, and also because a range of diverse symptoms have been ascribed to menopause. We investigated the prevalence and severity of symptoms from the late reproductive stage to late postmenopause, identifying those which might best differentiate menopause onset. METHODS: The Australian Women's Midlife Years (AMY) Study was a nationally representative cross-sectional study of women aged 40-69 years who were recruited via a non-probability panel using online and offline sources between Oct 27, 2023, and March 19, 2024. To be eligible, participants needed to be able to complete a questionnaire in English. Menopausal symptoms were assessed using the Menopause-specific Quality of Life (MENQOL) questionnaire. Symptom prevalence and severity over the previous 4 weeks was calculated with 95% CIs, with prevalence ratios adjusted for age, BMI, and other demographic variables. FINDINGS: 8096 women were recruited: 5509 women were classified using STRAW+10 as premenopausal (n=1250), early perimenopausal (n=344), late perimenopausal (n=271), and postmenopausal (n=3644). Among moderately-to-severely bothersome symptoms, hot flushes showed the greatest change in prevalence from premenopause (8·8% [95% CI 7·2-10·4]) to late perimenopause (37·3% [31·5-43·0]; adjusted prevalence ratio 4·74 [95% CI 3·64-6·19]). Less variation was apparent for other symptoms, including poor memory and low mood. Vaginal dryness was the most discriminative sexual symptom from premenopause to late perimenopause (adjusted prevalence ratio 2·54 [95% CI 1·78-3·61]). Women with vasomotor symptoms and changed menstrual flow had more prevalent moderately-to-severely bothersome symptoms compared with women without vasomotor symptoms. Compared with premenopausal women with vasomotor symptoms and changed menstrual flow, early perimenopausal women with vasomotor symptoms reported a higher prevalence of poor memory (adjusted prevalence ratio 1·36 [95% CI 1·06-1·75]). INTERPRETATION: Our findings suggest that moderately-to-severely bothersome vasomotor symptoms can reliably indicate the onset of perimenopause in women with oligomenorrhoea or amenorrhoea. Although other symptoms might be caused or exacerbated by menopause, other factors contributing to their occurrence need to be considered and included in management and care. Additionally, treatment options and care pathways are crucial to improve wellbeing during the perimenopause. FUNDING: National Health and Medical Research Council. TRANSLATIONS: For the Chinese and Spanish translations of the abstract see Supplementary Materials section.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Islam RM, Bond M, Ghalebeigi A, et al. Prevalence and severity of symptoms across the menopause transition: cross-sectional findings from the Australian Women's Midlife Years (AMY) Study. Lancet Diabetes Endocrinol. 2025. PMID: 40720963. doi:10.1016/S2213-8587(25)00138-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。